The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core |
| |
| Authors: | William J Jagust Dan Bandy Kewei Chen Norman L Foster Susan M Landau Chester A Mathis Julie C Price Eric M Reiman Daniel Skovronsky Robert A Koeppe |
| |
| Institution: | 1. Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA;2. Lawrence Berkeley National Laboratory, Berkeley, CA, USA;3. Banner Alzheimer''s Institute and Banner Good Samaritan PET Center, Phoenix, AZ, USA;4. Translational Genomics Research Institute, University of Arizona, Phoenix, AZ, USA;5. Arizona Alzheimer''s Consortium, Phoenix, AZ, USA;6. Department of Mathematics, Arizona State University, Tempe, AZ, USA;7. Center for Alzheimer''s Care, Imaging and Research and Department of Neurology, University of Utah, Salt Lake City, UT, USA;8. Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA;9. Avid Radiopharmaceuticals, Inc, Philadelphia, PA, USA;10. Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA;11. Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA;1. Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA;2. Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA;1. Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA;2. Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA;3. Department of Pathology, Stritch School of Medicine, Loyola University, Maywood, IL, USA;4. Department of Neurology, University of California, Davis, CA, USA;5. Department of Molecular Imaging & Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia;6. Department of Neurology, University of Pittsburgh, PA, USA;7. Department of Psychiatry, University of Pittsburgh, PA, USA;8. Department of Radiology, Mayo Clinic, Rochester, MN, USA;9. Alzheimer''s Disease Center, Department of Pathology, University of California Davis, CA, USA;10. Alzheimer''s Disease Research Center, University of Pittsburgh, PA, USA;11. Department of Pathology, University of Pittsburgh, Pennsylvania, USA;12. Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA;13. Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA;14. The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia;15. Department of Radiology, University of Pittsburgh, PA, USA;p. Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia;q. Biomedical Isotope Facility, MBIB Division, Lawrence Berkeley National Laboratory, CA, USA;r. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA;s. Department of Neurology, Mayo Clinic, Rochester, MN, USA;t. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA;1. Department of Radiology, Mayo Clinic, Rochester, MN, USA;2. Department of Neurology, Mayo Clinic, Rochester, MN, USA;3. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA;4. Department of Psychology, Mayo Clinic, Rochester, MN, USA;1. Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA;2. Department of Radiology, University of California, San Francisco, CA, USA;3. Department of Medicine, University of California, San Francisco, CA, USA;4. Department of Psychiatry, University of California, San Francisco, CA, USA;5. Department of Neurology, University of California, San Francisco, CA, USA;6. Alzheimer''s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA;7. Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA;8. Knight Alzheimer''s Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA;9. Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA;10. Division of Genetics, Department of Medicine, Brigham and Women''s Hospital and Harvard Medical School, Boston, MA, USA;11. Department of Radiology, Mayo Clinic, Rochester, MN, USA;12. Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA;13. Department of Neurology, Mayo Clinic, Rochester, MN, USA;14. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA;15. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA;p. Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA;q. Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA;r. Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;s. Alzheimer''s Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;t. Udall Parkinson''s Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;u. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;1. Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA;2. Department of Radiology, University of California, San Francisco, CA, USA;3. Department of Medicine, University of California, San Francisco, CA, USA;4. Department of Psychiatry, University of California, San Francisco, CA, USA;5. Department of Neurology, University of California, San Francisco, CA, USA;6. Alzheimer''s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA;7. Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA;8. Knight Alzheimer''s Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA;9. Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA;10. Division of Genetics, Department of Medicine, Brigham and Women''s Hospital and Harvard Medical School, Boston, MA, USA;11. Department of Radiology, Mayo Clinic, Rochester, MN, USA;12. Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA;13. Department of Neurology, Mayo Clinic, Rochester, MN, USA;14. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA;15. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA;p. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;q. Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA;r. Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;s. Alzheimer''s Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;t. Udall Parkinson''s Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;1. Department of Psychiatry, University of California–San Francisco, San Francisco, CA, USA;2. Department of Neurology and Center for Neuroscience, University of California–Davis, Sacramento, CA, USA;3. Helen Wills Neuroscience Institute, University of California–Berkeley, Berkeley, CA, USA;4. Division of Biostatistics, Department of Public Health Sciences, University of California–Davis, Davis, CA, USA |
| |
| Abstract: | BackgroundThis is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core.MethodsThe Core has supervised the acquisition, quality control, and analysis of longitudinal 18F]fluorodeoxyglucose PET (FDG-PET) data in approximately half of the ADNI cohort. In an “add on” study, approximately 100 subjects also underwent scanning with 11C] Pittsburgh compound B PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used many different approaches to characterize differences between subject groups (Alzheimer's disease, mild cognitive impairment, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG-PET as a potential outcome measure in clinical trials.ResultsADNI data indicate that FDG-PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. Pittsburgh compound B PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the 18F]-labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites.ConclusionsADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
